Neurocrine Biosciences, Inc. Revenue 2009–2025
Neurocrine Biosciences, Inc. reported $2.86B of revenue for fiscal 2025. That was 21.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +173.5%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $2.86B | +21.4% |
| FY 2024 | $2.36B | +24.8% |
| FY 2023 | $1.89B | +26.8% |
| FY 2022 | $1.49B | +31.3% |
| FY 2021 | $1.13B | +8.4% |
| FY 2020 | $1.05B | +32.7% |
| FY 2019 | $788.10M | +74.7% |
| FY 2018 | $451.20M | +179.2% |
| FY 2017 | $161.63M | +977.5% |
| FY 2016 | $15.00M | -24.1% |
| FY 2015 | $19.77M | — |
| FY 2014 | $0 | -100.0% |
| FY 2013 | $2.92M | -94.5% |
| FY 2012 | $53.14M | -31.4% |
| FY 2011 | $77.41M | +131.1% |
| FY 2010 | $33.50M | +1034.5% |
| FY 2009 | $2.95M | — |
Source: Neurocrine Biosciences, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open NBIX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Neurocrine Biosciences, Inc. reported $2.86B of revenue for fiscal 2025. That was 21.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +173.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Neurocrine Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeurocrine Biosciences, Inc. — frequently asked questions
What is Neurocrine Biosciences, Inc.'s revenue?
Neurocrine Biosciences, Inc. (NBIX) reported revenue of $2.86B for fiscal year 2025, per its SEC filings.
How has Neurocrine Biosciences, Inc.'s revenue changed over time?
Between fiscal 2009 and 2025, NBIX's revenue grew at roughly 53.7% per year (compound annual rate), from $2.95M to $2.86B.
Where does this data come from?
Figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.